concentraat voor oplossing voor infusie
Sponsors
Hopital Erasme, Princess Maxima Center For Pediatric Oncology, Gilead Sciences Inc., Amsterdam UMC, Revolution Medicines Inc.
Conditions
Acute lymphoblastic leukemiaAdvanced Non-Small Cell Lung CancerBorderline resectable pancreatic cancer (BRPC)Breast cancerDisseminated cancerInflammation of sternal regionLung CancerPancreatic adenocarcinoma
Phase 1
Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group
RecruitingCTIS2023-508707-20-00
Start: 2024-09-19Target: 66Updated: 2025-12-15
Study of RMC-6291, With or Without RMC-6236, in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
RecruitingCTIS2023-509571-16-00
Start: 2024-07-17Target: 162Updated: 2025-12-17
A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B
RecruitingCTIS2023-509572-42-00
Start: 2024-07-17Target: 180Updated: 2026-01-13
A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)
Not yet recruitingCTIS2025-521577-13-00
Target: 64Updated: 2025-09-11
Phase 2
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma:
a randomised comparative multicentre phase II study (STEREOPAC)
RecruitingCTIS2022-501181-22-01
Start: 2023-02-06Target: 256Updated: 2024-01-10
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Active, not recruitingCTIS2022-502916-35-01
Start: 2024-03-27Target: 171Updated: 2025-09-10
Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial
RecruitingCTIS2024-510576-21-00
Start: 2024-09-18Target: 100Updated: 2024-07-09
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)
Not yet recruitingCTIS2024-512318-16-00
Target: 40Updated: 2026-01-02
Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastases. - The PUMP-IT study (M19PIT)
Active, not recruitingCTIS2024-515525-28-00
Start: 2020-09-10Target: 31Updated: 2024-11-27
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)
RecruitingCTIS2024-515080-54-00
Start: 2019-08-15Target: 120Updated: 2025-07-29
Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 trial
Active, not recruitingCTIS2024-513217-12-00
Start: 2020-02-04Target: 34Updated: 2025-01-13
Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial
RecruitingCTIS2025-521158-40-00
Start: 2025-09-12Target: 12Updated: 2025-08-27
Phase 3
Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
SuspendedCTIS2022-502503-30-00
Start: 2022-12-15Target: 206Updated: 2026-01-27
PAmidronate for Pain in Sternocostoclavicular hyperostosis: the PAPS-study, a double-blind randomized placebo-controlled trial (PAPS)
RecruitingCTIS2023-510309-16-00
Start: 2020-12-08Target: 70Updated: 2025-01-16
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)
Not yet recruitingCTIS2024-516260-29-00
Target: 368Updated: 2024-10-09
TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort
Not yet recruitingCTIS2023-509465-20-00
Target: 184Updated: 2024-10-28
Phase 4
Decrease of intraoperative fluid administration in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) with vasopressin (HiPRESS)
RecruitingCTIS2024-513598-33-00
Start: 2025-01-21Target: 70Updated: 2025-11-03
Lantiolihaspuudutuksen vaikutus munuaisen poistoleikkauksen jälkeiseen kivun hoitoon ja toipumiseen
Not yet recruitingCTIS2024-519910-30-00
Target: 90Updated: 2025-01-21